Biotest (BIO3) AI Stock Analysis

• Market Cap: €1.44B
• Dividend Yield: 0.27%
• Average Volume (3M): 7.51K
• Price to Earnings (P/E): 45.0
• Beta (1Y): 0.04
• Revenue Growth: 6.09%
• EPS Growth: -79.21%
• Country: DE
• Employees: 2,495
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 19,785,727
• 10 Day Avg. Volume: 2,866
• 30 Day Avg. Volume: 7,512
• PEG Ratio: -0.73
• Price to Book (P/B): 2.24
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 44.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Biotest's financial performance shows growth but with some risks, notably in profit margins and leverage. Technical indicators are positive, suggesting bullish momentum. However, the high P/E ratio and low dividend yield indicate potential overvaluation. Overall, the stock presents a moderate risk-reward profile.

Biotest Business Overview & Revenue Model

Company Description

Biotest AG, listed under the ticker BIO3, is a leading global company specializing in the development, manufacturing, and marketing of plasma protein products and biotherapeutic drugs. Operating primarily in the healthcare and pharmaceuticals sector, Biotest focuses on providing innovative solutions for diseases in immunology, hematology, and intensive care medicine. The company's core products include immunoglobulins, coagulation factors, and albumins derived from human blood plasma, which are crucial for treating patients with immune deficiencies, coagulation disorders, and other serious health conditions.

How the Company Makes Money

Biotest AG generates revenue through the production and sale of plasma-derived products and biotherapeutic drugs. The company's key revenue streams include the sale of its core products—immunoglobulins, coagulation factors, and albumins—to hospitals, healthcare providers, and pharmaceutical distributors worldwide. Biotest also engages in strategic partnerships and collaborations with other pharmaceutical companies to enhance its product development and reach. Additionally, Biotest invests in research and development to innovate and expand its product offerings, thereby driving further sales growth. The company benefits from its global distribution network and regulatory approvals, which enable it to penetrate various international markets.

Biotest Financial Statement Overview

Summary

Biotest has shown revenue growth and improved operational efficiency. However, a decline in net profit margin and increased leverage are concerning. While cash flows have improved, cash conversion efficiency remains a challenge. The overall financial health is stable but with risks.

Income Statement

Biotest has shown a positive revenue growth from 2019 to 2024 with a compound annual growth rate. The gross profit margin improved significantly from the previous years but remains moderate. However, the net profit margin has fallen drastically in 2024 compared to 2023, indicating decreased profitability. The EBIT and EBITDA margins have shown improvement over the years, indicating better operational efficiency.

Balance Sheet

The debt-to-equity ratio has increased, indicating higher leverage, which could pose financial risk. The return on equity (ROE) declined in 2024 due to lower net income. The equity ratio has improved modestly, reflecting a stable capital structure.

Cash Flow

Free cash flow turned positive in 2024, showing improvement in cash management. However, the operating cash flow to net income ratio is low, indicating potential issues with cash conversion. The free cash flow to net income ratio has improved but still reflects challenges in converting income into cash.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
726.20M	684.60M	516.10M	515.60M	484.20M
	Gross Profit
223.80M	280.30M	124.90M	80.70M	130.10M
	EBIT
94.50M	143.50M	-13.00M	-52.10M	-13.20M
	EBITDA
120.40M	179.00M	28.30M	-17.70M	16.00M
	Net Income Common Stockholders
26.40M	127.00M	-31.60M	-63.30M	-31.40M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
119.50M	118.50M	136.60M	117.50M	89.20M
	Total Assets
1.43B	1.41B	1.20B	1.10B	1.13B
	Total Debt
597.20M	689.80M	574.30M	496.30M	469.10M
	Net Debt
489.40M	581.70M	457.70M	391.90M	397.80M
	Total Liabilities
903.30M	912.00M	831.90M	723.80M	689.70M
	Stockholders Equity
530.70M	498.90M	371.10M	380.40M	441.60M
Cash Flow		Free Cash Flow
32.20M	-36.10M	-69.80M	15.70M	-43.70M
	Operating Cash Flow
60.90M	-2.70M	-40.50M	33.90M	-16.70M
	Investing Cash Flow
-25.70M	1.30M	-37.00M	-23.40M	-14.60M
	Financing Cash Flow
-35.40M	-6.80M	89.60M	22.60M	42.00M

Biotest Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 30.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BIO3, the sentiment is Neutral. The current price of 30 is below the 20-day moving average (MA) of 30.08, above the 50-day MA of 29.77, and above the 200-day MA of 27.80, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 50.93 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:BIO3.

Biotest Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RHM	68 Neutral	€72.17B	92.03	21.45%	0.36%	41.65%	42.12%
PAH3	67 Neutral	€11.67B	2.31		6.72%	―	―
FME	65 Neutral	€14.91B	24.12	4.37%	2.34%	0.10%	27.83%
BIO3	63 Neutral	€1.44B	44.96	5.13%	0.27%	6.09%	-79.21%
SRT3	63 Neutral	€14.54B	168.51	3.55%	0.32%	3.99%	-36.36%
BAYN	56 Neutral	€23.64B	―	-9.56%	0.43%	-0.92%	-4.30%
Sector *	52 Neutral	$5.22B	3.55	-44.39%	2.82%	15.40%	-0.09%